热门资讯> 正文
Exelixis因第二季度失误和管道更新而下滑12%
2025-07-29 06:12
- 纳比特(NA) 0
- 盛大科技(SDA) 0
- 伊克力西斯(EXEL) 0
- Exelixis (NASDAQ:EXEL) is down ~12% in after-hours trading Monday after posting Q2 financial results that missed on both lines.
- The company is maintaining its financial guidance for 2025.
- The biotech also said that it will not move candidate zanzalintinib into phase 3 for advanced squamous cell carcinoma of the head and neck. It cited emerging phase 2 data, competition in the indication, and other, possibly larger commercial opportunities. However, zanzalintinib remains in phase 3 for colorectal cancer and non-clear cell renal cell carcinoma.
- In Q2, non-GAAP diluted EPS fell to $0.75 from $0.84 in the year-ago period.
- Total revenue declined ~11% year over year largely as the result of a significant drop in collaboration revenues compared to Q2 2024.
More on Exelixis
- Exelixis: I Was Wrong To Be Too Cautious (Rating Upgrade)
- Exelixis: Zanzalintinib MOA Overcomes Competing CRC Regorafenib Treatment
- Exelixis: A Notable Quarter
- Exelixis Q2 2025 Earnings Preview
- Ipsen granted EU nod for Exelixis-partnered cancer drug for neuroendocrine tumors
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
